COMPASS Pathways is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.
The company is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.
The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative fervor surrounding a potential multi-billion-dollar acquisition of the company began to dissolve, leaving investors to grapple with a "news
Fourth-quarter revenue increased 3% from a year earlier to $3.88 billion, topping Wall Street expectations of $3.78 billion, according to Fiscal.ai data.
The U.S. Food and Drug Administration cleared its Investigational New Drug application for SER-252, a therapy to treat patients with Parkinson’s disease.
The healthcare landscape underwent a seismic shift in 2024, as the industry’s major players pivoted away from traditional hardware toward high-margin diagnostic platforms and artificial intelligence (AI)-integrated imaging software. This strategic realignment resulted in a massive $25.7 billion year-over-year jump in deal value for the diagnostics and
The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year downturn that plagued the market between 2022 and 2024. This resurgence is not merely a product of
Investors remain divided on Moderna and Super Micro as heavy short interest reflects skepticism, yet recent catalysts suggest both names could still deliver unpredictable, sentiment-driven swings.
